Immunomodulatory activity of dipeptidyl peptidase-4 inhibitors in immune-related diseases

dc.citation.spage	2250302
dc.citation.volume	53
dc.contributor.author	Drakul, Marija
dc.contributor.author	Čolić, Miodrag
dc.date.accessioned	2024-11-22T12:38:35Z
dc.date.available	2024-11-22T12:38:35Z
dc.date.issued	2023
dc.description.abstract	Dipeptidyl peptidase-4 (DPP-4), also known as CD26, is a 110-kDa cell surface glycoprotein with enzymatic and signal transducing activity. DPP-4/CD26 is expressed by various cells, including CD4+ and CD8+ T cells, B cells, dendritic cells, macrophages, and NK cells. DPP-4 inhibitors (DPP-4i) were introduced to clinics in 2006 as new oral antihyperglycemic drugs approved for type 2 diabetes mellitus treatment. In addition to glucose-lowering effects, emerging data, from clinical studies and their animal models, suggest that DPP-4i could display anti-inflammatory and immunomodulatory effects as well, but the molecular and immunological mechanisms of these actions are insufficiently investigated. This review focuses on the modulatory activity of DPP-4i in the immune system and the possible application of DPP-4i in other immune-related diseases in patients with or without diabetes.
dc.identifier.doi	10.1002/eji.202250302
dc.identifier.uri	https://vaseljena.ues.rs.ba/handle/123456789/1336
dc.language.iso	en
dc.publisher	Wiley
dc.source	European Journal of Immunology
dc.subject	Autoimmunity - DPP-4/CD26 - Gliptins - Glycoprotein - Immunomodulation
dc.title	Immunomodulatory activity of dipeptidyl peptidase-4 inhibitors in immune-related diseases
dc.type	Article

Сада се приказује 1 - 1 од 1

Сада се приказује 1 - 1 од 1